07:22 AM EDT, 06/10/2024 (MT Newswires) -- ProKidney ( PROK ) said its phase 2 REGEN-007 trial of rilparencel as a potential treatment for chronic kidney disease caused by diabetes yielded "positive interim results."

The ongoing trial includes diabetes patients with chronic kidney disease. In one group, patients with at least 12 months follow-up showed stabilized kidney function for 18 months.

"[T]he interim results from REGEN-007 are promising and reveal the potential of rilparencel to preserve kidney function in patients with moderate to severe [chronic kidney disease]," ProKidney ( PROK ) Chief Executive Bruce Culleton said.

Shares of the company were up more than 3% in recent Monday premarket activity.

Price: 3.3100, Change: +0.12, Percent Change: +3.76